Glioma‐derived galectin‐1 regulates innate and adaptive antitumor immunity
Open Access
- 9 August 2013
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 134 (4) , 873-884
Abstract
Galectin‐1 is a glycan‐binding protein, which is involved in the aggressiveness of glioblastoma (GBM) in part by stimulating angiogenesis. In different cancer models, galectin‐1 has also been demonstrated to play a pivotal role in tumor‐mediated immune evasion especially by modulating cells of the adaptive immune system. It is yet unknown whether the absence or presence of galectin‐1 within the glioma microenvironment also causes qualitative or quantitative differences in innate and/or adaptive antitumor immune responses. All experiments were performed in the orthotopic GL261 mouse high‐grade glioma model. Stable galectin‐1 knockdown was achieved via transduction of parental GL261 tumor cells with a lentiviral vector encoding a galectin‐1‐targeting miRNA. We demonstrated that the absence of tumor‐derived but not of host‐derived galectin‐1 significantly prolonged the survival of glioma‐bearing mice as such and in combination with dendritic cell (DC)‐based immunotherapy. Both flow cytometric and pathological analysis revealed that the silencing of glioma‐derived galectin‐1 significantly decreased the amount of brain‐infiltrating macrophages and myeloid‐derived suppressor cells (MDSC) in tumor‐bearing mice. Additionally, we revealed a pro‐angiogenic role for galectin‐1 within the glioma microenvironment. The data provided in this study reveal a pivotal role for glioma‐derived galectin‐1 in the regulation of myeloid cell accumulation within the glioma microenvironment, the most abundant immune cell population in high‐grade gliomas. Furthermore, the prolonged survival observed in untreated and DC‐vaccinated glioma‐bearing mice upon the silencing of tumor‐derived galectin‐1 strongly suggest that the in vivo targeting of tumor‐derived galectin‐1 might offer a promising and realistic adjuvant treatment modality in patients diagnosed with GBM.Keywords
Funding Information
- Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT Vlaanderen)
- Klinisch Onderzoeksfonds UZ Leuven
- Fund for Scientific Research, Flanders (FWO-V)
- Fonds National de la Recherche Scientifique (FRS-FNRS Belgium)
- Herman Memorial Research Fund
- Olivia Hendrickx Research Fund
- James E. Kearney Foundation
- Belgian Brain Tumor Support (BBTS)
This publication has 41 references indexed in Scilit:
- Metabolic Inhibition of Galectin-1-Binding Carbohydrates Accentuates Antitumor ImmunityJournal of Investigative Dermatology, 2012
- Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironmentClinical and Experimental Immunology, 2012
- Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapyJournal of Neuro-Oncology, 2010
- Galectins and GliomasBrain Pathology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma MultiformeClinical Cancer Research, 2008
- Galectin-1 Is a Novel Structural Component and a Major Regulator of H-Ras NanoclustersMolecular Biology of the Cell, 2008
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapyProceedings of the National Academy of Sciences, 2006